BridgeBio Pharma shares slid -3.9% this afternoon. Here's what you need to know about the Mid-CapPharmaceutical company:
-
BridgeBio Pharma has logged a 78.0% 52 week change, compared to 12.7% for the S&P 500
-
BBIO has an average analyst rating of buy and is -27.09% away from its mean target price of $59.16 per share
-
Its trailing earnings per share (EPS) is $-3.56, which brings its trailing Price to Earnings (P/E) ratio to -12.1. The Health Care sector's average P/E ratio is 22.94
-
The company's forward earnings per share (EPS) is $-3.06 and its forward P/E ratio is -14.1
-
The current ratio is currently 4.7, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $-521659000 and the average free cash flow growth rate is -15.3%
-
BridgeBio Pharma's revenues have an average growth rate of 40.5% with operating expenses growing at -6.1%. The company's current operating margins stand at -267.2%